Comment on CMS-2026-1256-0002
Boston Scientific CorporationOpposeBusiness
Summary: Boston Scientific Corporation opposes the proposed repeal of the Alternative Pathways for New Technology Add-on Payment (NTAP) and Outpatient Prospective Payment System (OPPS) Device Pass-Through. The company argues that these pathways are essential for interagency collaboration and streamlining the transition of breakthrough technologies from the FDA to Medicare coverage.
Boston Scientific Corporation appreciates the opportunity to provide comments in response to the Centers for Medicare & Medicaid Services Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System Proposed Rule for Fiscal Year 2027. Our comments are attached.